Mirum Pharmaceuticals (MIRM) Operating Income (2019 - 2026)

Mirum Pharmaceuticals' Operating Income history runs 8 years deep, the most recent figure standing at -$789.5 million for Q1 2026.

• In Q1 2026, Operating Income fell 5099.66% year-over-year to -$789.5 million; the TTM figure through Mar 2026 stood at -$796.4 million (down 943.51% YoY), while the FY2025 annual figure was -$22.1 million, up 74.73% from the prior year.
• Operating Income for Q1 2026 stood at -$789.5 million, down from -$4.6 million in the prior quarter.
• The five-year high for Operating Income was $2.6 million in Q3 2025, with the low at -$789.5 million in Q1 2026.
• The 5-year median for Operating Income is -$25.1 million (2023), against an average of -$67.0 million.
• The sharpest annual moves came in 2025 and 2026: Operating Income surged 120.52% in 2025, then sank 5099.66% in 2026.
• Mirum Pharmaceuticals' Operating Income stood at -$34.2 million in 2022, then grew by 4.61% to -$32.6 million in 2023, then gained by 25.67% to -$24.2 million in 2024, then surged by 81.15% to -$4.6 million in 2025, then tumbled by 17186.29% to -$789.5 million in 2026.
• Business Quant data shows MIRM's Operating Income at -$789.5 million in Q1 2026, -$4.6 million in Q4 2025, and $2.6 million in Q3 2025.